Overview

A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema

Status:
Completed

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the proportion of patients with a 10 letters gain on Best Corrected Visual Acuity (BCVA) at 6 months in current medical practice.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Ranibizumab